Abstract
Menopause is a critical period in a woman’s life, which is accompanied by complex physiological, psycho-emotional, and metabolic changes that significantly affect quality of life. An important pathogenetic mechanism during this period is the development of endothelial dysfunction and the reduction of nitric oxide (NO) bioavailability, which leads to impaired vascular reactivity, increased risk of cardiovascular disease, and intensification of vasomotor symptoms (VMS). L-arginine, as the main substrate for NO synthase, is considered a promising non-hormonal agent for the correction of menopausal disorders, it is able to influence on vascular, metabolic, and sexual function, as well as the overall well-being of women in peri- and postmenopause. The aim of this work was to summarize current data on the role and clinical effectiveness of L-arginine in the management of menopausal symptoms.A systematic analytical review of clinical studies which were published in international databases (PubMed, Scopus, Cochrane Library, Web of Science) and local sources from 2010 to 2025 was conducted. The analysis included randomized controlled trials and large prospective cohort studies that evaluated the effectiveness of oral L-arginine of the following indications: reduction of the frequency and intensity of VMS, correction of menopausal endotheliopathy, improvement of sexual function, and its impact on microcirculation, lipid metabolism, glycemic markers, and the severity of climacteric syndrome (Kupperman index, Menopause-Specific Quality of Life Questionnaire – MENQOL, The Short Form-36 Health Survey – SF-36).The results of the analysis indicate that L-arginine contributes to a significant improvement in endothelial function, reduction of triglycerides, total cholesterol, low-density lipoproteins, and fasting glucose. In most studies, a statistically significant decrease in the Kupperman index and the frequency of VMS was observed, confirming its clinical effectiveness in correction of climacteric manifestations. Data on improvements in quality of life according to MENQOL and SF-36 scales remain heterogeneous, with the most pronounced effects reported in studies of combined nutrient supplements. At the same time, L-arginine is characterized by good tolerability and a favorable safety profile, with adverse effects limited to mild gastrointestinal symptoms.Thus, L-arginine is a promising non-hormonal agent in the management of menopausal symptoms due to its effect on the “L-arginine – NO – cyclic guanosine monophosphate – vasodilation” pathway. Its use improves vascular and metabolic parame-ters, reduces the severity of climacteric manifestations, and may positively influence sexual function and the overall well-being of women in peri- and postmenopause. Further large-scale randomized trials are needed to confirm these findings, standardize dosages, and determine the long-term effects of therapy.

This publication has 42 references indexed in Scilit: